![]() ![]() Exploratory studies in patients with CKD have found that supplementation with vitamin D has resulted in reduced circulating levels of inflammatory proteins ( 5), improved glycemic control ( 6), and reduced need for erythropoiesis-stimulating agents ( 7, 8). Although the clinical benefits in these patients have not been defined by many randomized controlled trials, observational studies have found an association between low 25(OH)D levels and mortality ( 4). In fact, the Kidney Disease: Improving Global Outcomes guidelines recommend using vitamin D in vitamin D-deficient patients in CKD stages 3–5D ( 2). Because the recent extrarenal metabolism and actions of vitamin D have been explored ( 1), there is a growing interest in using vitamin D supplementation (ergocalciferol or cholecalciferol) in patients with CKD ( 2, 3). ![]() It was previously believed that the kidney was the sole site of 1- α hydroxylase activity therefore, there was no role for supplementing CKD patients on dialysis with vitamin D, because it would not be metabolized to the active form. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |